WuXi AppTec has announced that has acquired Pharmapace (San Diego, California), a clinical research services company with expertise in providing biometrics services for all phases of clinical trials, regulatory submissions, and post marketing support. Pharmapace will become a wholly owned subsidiary of WuXi Clinical and will continue to focus on growing its core biometrics competences and integrate with WuXi Clinical’s other clinical development services.
Pharmapace, which was founded in 2013, provides a full range of biometrics services for all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing. The acquisition enables WuXi Clinical to expand its biometrics capabilities in the US and Europe. By integrating Pharmapace and WuXi Clinical biometrics teams, WuXi Clinical will be able to provide its customers with efficient and cost-effective biometrics services, the company says.
“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services,” says Edward Hu, co-CEO, WuXi AppTec. “Together, we [will be] able to shorten time-to-market of new drugs and to achieve the dream that ‘every drug can be made and every disease can be treated’,” Hu says.
By Michael Ravenscroft
Source: Chemical Week
The separation is expected to be completed by early Q3, following the receipt of all relevant approvals, including final Board approval. Nouryon intends to reduce its own debt with proceeds received from a planned external financing by Nobian.
Trinseo became a producer of the resin when it acquired Arkema’s PMMA business. It announced that it closed on the €1.14bn deal earlier this month.
As part of the EU’s Single-Use Plastic Directive (SUPD), it will become mandatory for caps and lids to remain attached to all beverage containers up to three liters in capacity from 2024.
